

Mechanical thrombectomy with combined stent retriever and contact aspiration versus stent retriever alone for acute large vessel occlusion: data from ANGEL-ACT registry

Xiaochuan Huo ¹, Dapeng Sun ¹, Mingkai Hu,¹ Raynald,¹ Baixue Jia ¹, Xu Tong ¹, Gaoting Ma ¹, Anxin Wang,² Ning Ma ¹, Feng Gao,¹ Dapeng Mo ¹, Zhongrong Miao,¹ the ANGEL-ACT Study group

To cite: Huo X, Sun D, Hu M, *et al.* Mechanical thrombectomy with combined stent retriever and contact aspiration versus stent retriever alone for acute large vessel occlusion: data from ANGEL-ACT registry. *Stroke & Vascular Neurology* 2023;8:e001765. doi:10.1136/svn-2022-001765

XH and DS contributed equally.

Received 30 May 2022

Accepted 22 December 2022

Published Online First

31 January 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

²China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Correspondence to

Dr Zhongrong Miao;
zhongrongm@163.com

ABSTRACT

Background and purpose An analysis of the ASTER 2 trial revealed similar final recanalisation levels and clinical outcomes in acute large vessel occlusion (LVO) stroke between stent retrieval (SR) alone as a first-line mechanical thrombectomy (MT) technique (SR alone first-line) and concomitant use of contact aspiration (CA) plus SR as a first-line MT technique (SR+CA first-line). The purpose of the present study was to compare the safety and efficacy of SR+CA first-line with those of SR alone first-line for patients with LVO in China.

Methods We conducted the present study by using the data from the ANGEL-ACT registry. We divided the selected patients into SR+CA first-line and SR alone first-line groups. We performed logistic regression and generalised linear models with adjustments to compare the angiographic and clinical outcomes, including successful/complete recanalisation after the first technique alone and all procedures, first-pass successful/complete recanalisation, number of passes, 90-day modified Rankin Scale, procedure duration, rescue treatment and intracranial haemorrhage within 24 hours.

Results Of the 1233 enrolled patients, 1069 (86.7%) received SR alone first-line, and 164 (13.3%) received SR+CA first-line. SR+CA first-line was associated with more thrombectomy passes (3 (2–4) vs 2 (1–2); $\beta=1.77$, 95% CI=1.55 to 1.99, $p<0.001$), and longer procedure duration (86 (60–129) min vs 80 (50–122) min; $\beta=10.76$, 95% CI=1.08 to 20.43, $p=0.029$) than SR alone first-line group. Other outcomes were comparable (all $p>0.05$) between the two groups.

Conclusions Patients undergoing SR+CA first-line had more thrombectomy passes and longer procedure duration than patients undergoing SR alone first-line. Additionally, we suggested that SR+CA first-line was not superior to SR alone first-line in final recanalisation level, first-pass recanalisation level and 90-day clinical outcomes in the Chinese population.

INTRODUCTION

The safety and efficacy of mechanical thrombectomy (MT) by stent retriever (SR) for acute anterior circulation proximal large

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ The ASTER 2 trial failed to demonstrate that stent retrieval (SR)+contact aspiration (CA) first-line was superior to SR alone first-line in final angiographic and clinical outcomes. However, in the Asian population, there are few comparative analyses between SR+CA first-line and SR alone first-line for large vessel occlusion (LVO).

WHAT THIS STUDY ADDS

⇒ Our study, including the patients from a prospective, multicentre registry study, found that the combination of SR and CA first-line was associated with more mechanical thrombectomy (MT) passes and longer procedure duration than SR alone first-line. However, SR+CA first-line may be more effective than SR alone first-line in certain patients with LVO, such as patients undergoing general anaesthesia or without atrial fibrillation. Furthermore, we confirmed the results of the ASTER 2 trial in that SR+CA first-line was not superior to SR alone in final recanalisation level, first-pass recanalisation level and 90-day clinical outcomes in the Chinese population.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY

⇒ Our results should be highly considered during the MT. Nevertheless, a large randomised controlled trial which is conducted in Asian countries is warranted.

vessel occlusion (LVO) have been proven by five randomised controlled trials (RCTs).¹ However, there are two main MT techniques: SR thrombectomy and contact aspiration (CA) thrombectomy by aspiration catheter (AC).² Two RCTs have demonstrated similar angiographic and clinical outcomes between SR and CA thrombectomy.^{3,4} As known to us, reperfusion is a strong predictor of good clinical outcomes in patients with LVO.⁵ Consequently, how to improve the reperfusion level

with the best technique is still a hot topic in the era of MT. Several observational studies reported the concomitant use of CA during SR (SR+CA) as a more efficient technique.^{6–11} However, the recent RCT—ASTER 2 (Combined Use of Contact Aspiration and the Stent Retriever Technique vs Stent Retriever Alone for Recanalization in Acute Cerebral Infarction)—demonstrated that SR+CA as first-line MT technique (SR+CA first-line) resulted in similar final angiographic and clinical outcomes with SR alone as first-line MT technique (SR alone first-line); the trial may have been underpowered to detect more minor differences between groups.¹²

Currently, in the Asian population, there are still few comparative analyses between SR+CA first-line and SR alone first-line for patients with LVO. As a result, we sought to investigate the safety and efficacy of SR+CA first-line compared with SR alone first-line for LVO in the Chinese population.

METHODS

Study population

From November 2017 to March 2019, the Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic Stroke (ANGEL-ACT) registry was a large prospective registry study and was carried out in 111 hospitals across 26 Chinese provinces, enrolling 1793 consecutive patients with LVO receiving endovascular thrombectomy (EVT). The previous study reported the complete registry methods of the ANGEL-ACT registry, including the data collection methods, inclusion/exclusion criteria, and imaging interpretation methods.¹³

We used data from the ANGEL-ACT registry in our analysis. Patients were excluded according to the following reasons: no EVT records, anterior cerebral artery (ACA) or posterior cerebral artery (PCA) occlusions, missing value for 90-day modified Rankin Scale (mRS), and CA first-line or intra-arterial thrombolysis (IAT) first-line or balloon angioplasty first-line or stenting first-line.

Data collection

All variables in our study were prospectively collected. The investigators who received training and got the qualification certificates recorded the National Institutes of Health Stroke Scale (NIHSS) and mRS scores.

The imaging interpretation was conducted by the imaging core laboratory, which was blinded to all clinical information. They assessed the images that included baseline brain CT, brain CT angiography, brain MRI, brain magnetic resonance angiography, digital subtraction angiography and brain CT after EVT. Alberta Stroke Program Early CT Score (ASPECTS) for the anterior LVO and posterior circulation ASPECTS for the posterior circulation LVO, tandem occlusion, underlying intracranial atherosclerosis disease (ICAD) (defined as more than 70% of fixed stenosis or more than 50% of fixed stenosis accompanied by distal blood flow impairment

or the repeated reocclusive evidence after MT),¹⁴ procedural complications including intraprocedural embolisation, vasospasm requiring treatment, artery perforation and artery dissection and modified Thrombolysis in Cerebral Infarction (mTICI)¹⁵ were included in the imaging interpretation. We used site-reported data when patients' images could not be obtained. The imaging review criteria were the same between local investigators and the core laboratory, except that previous images indicated fixed stenosis at the occlusion site, which could also determine underlying ICAD.

Thrombectomy procedures

SR alone thrombectomy technique

The guide catheter was advanced over a 5 French/125 cm catheter and a 0.035-inch guidewire into the internal carotid arterial segment of interest or dominant vertebral arterial segment of interest. The microcatheter (0.021–0.027-inch inner lumen) was navigated through the thrombus to the distal end of the target artery by a microwire (0.014-inch diameter). Then, the SR was advanced through the microcatheter and deployed across the thrombus. Finally, about 5 min after deploying SR, the SR was withdrawn.

SR+CA thrombectomy technique

The guide catheter was advanced over a 5 French/125 cm catheter and a 0.035-inch guidewire into the internal carotid arterial segment of interest or dominant vertebral arterial segment of interest. A microcatheter (0.021–0.027-inch inner lumen) with a microwire (0.014-inch diameter) was used to guide the AC to the thrombus proximal end, and then, the microwire guided the microcatheter through the thrombus to the distal end of the occlusive artery. Then, the SR was advanced through the microcatheter and deployed across the thrombus (we recommended the microcatheter be withdrawn before thrombus extraction to increase the aspirational cross-sectional luminal area). Finally, about 5 min after deploying SR, we withdrew SR into the AC or withdrew the SR+AC as one unit under continuous aspiration using the AC. The CA was applied using a 50 mL syringe manually or an aspiration pump.

Devices

The following types of SR were used: Trevo (Stryker), Reco (Jiangsu Nico), Revive (Cordis) or Solitaire FR (Medtronic) device. The following ACs were used: Penumbra ACE60 reperfusion catheter (Penumbra), Catalyst 5/6 (Stryker), Sofia/Sofia plus (Microvention) or Navien 058/072 (Medtronic).¹⁶

Only trained and experienced neurointerventionists were allowed to perform MT for LVO in the ANGEL-ACT registry, and the first-line thrombectomy technique selection was as per the neurointerventionists' preference.

Outcome measure

Successful recanalisation of the target artery after the first technique alone was the primary outcome. The

secondary outcomes included complete recanalisation after first technique alone, first-pass successful/complete recanalisation, procedure duration, number of MT attempts, successful/complete recanalisation after all procedures, rescue treatment (switching to another thrombectomy technique after three attempts and balloon angiography/stenting), change in NIHSS score at 24 hours, 90-day mRS ordinal distribution, 90-day mRS of 0–1, 0–2, 0–3 as dichotomous variables. According to the standardised interview protocol, the trained investigator, who was blinded to clinical information, assessed the mRS score through the interview over the phone. Intraprocedure embolisation, parenchymal haemorrhage (PH) type 1 within 24 hours, PH2 within 24 hours, any intracranial haemorrhage (ICH) within 24 hours, symptomatic ICH (SICH) within 24 hours and 90-day mRS 6 were the safety outcomes. PH1, PH2, any ICH and SICH were assessed according to Heidelberg Bleeding Classification.¹⁷ Successful recanalisation was defined as mTICI of more than 2b grade, and complete recanalisation was defined as mTICI of 3 grade.

Statistical analysis

All statistical analyses were performed using SAS V.9.4 software (SAS Institute). We described variables using the median (IQR) and number (percentages) for continuous variables and categorical variables, respectively. We conducted the Pearson χ^2 or Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables as the univariable analyses. In order to compare the outcomes, we performed the binary logistic regression analysis, generalised linear analysis or ordinal logistic regression analysis, to analyse the adjusted ORs, β -coefficients or common OR with their 95% CIs. The potential confounders included in the above multivariable analyses were the variables with a *p* value of <0.05 in the univariable analyses. Furthermore, we adjusted the propensity score (PS) that was calculated by the logistic regression analysis, including all the baseline characteristics. We also explored the interactive effect between the MT first-line options and the following subgroups on the primary outcomes: age (<65 years old vs ≥65 years old), gender (male sex vs female sex), admission NIHSS (<15 vs ≥15), atrial fibrillation (yes vs no), pretreatment with intravenous thrombolysis (IVT) (yes vs no), underlying ICAD (yes vs no), occlusion sites (internal carotid artery vs middle cerebral artery (MCA) M1 segment vs MCA M2 segment vs vertebrobasilar artery), tandem occlusion (yes vs no), TOAST stroke subtypes (Trial of ORG 10172 in Acute Stroke Treatment criteria) (large arterial atherosclerosis (LAA) vs cardioembolism vs other or unknown aetiology vs undetermined aetiology), general anaesthesia (GA) (yes vs no). The interaction effect was tested by a logistic regression analysis that enrolled the corresponding multiplicative interaction term with adjustment for PS. Statistical significance was determined by a two-sided *p* value of <0.05.

RESULTS

Five hundred and sixty patients were excluded for the reasons listed below: (1) no EVT records (*n*=25); (2) ACA or PCA occlusions (*n*=37); (3) missing value for 90-day mRS (*n*=64); and (4) CA first-line or IAT first-line or balloon angioplasty first-line or stenting first-line (*n*=434). Finally, 1233 patients were enrolled in our study, of whom 1069 (86.7%) received SR alone first-line, and 164 (13.3%) received SR+CA first-line (figure 1).

Baseline information

In univariate analyses, patients from SR alone first-line group had lower median age (65 (55–73) vs 69 (58–77), *p*=0.007), lower atrial fibrillation rate (34.1% vs 46.3%, *p*=0.002), lower pretreatment with IVT rate (26.2% vs 33.5%, *p*=0.049), higher tandem occlusion rate (14.7% vs 7.3%, *p*=0.011), higher GA rate (41.2% vs 26.8%, *p*=0.001) and higher heparin rate during the procedure (51.1% vs 40.2%, *p*=0.010) than SR+CA first-line group. Other baseline characteristics were similar (all *p*>0.05) between SR alone first-line and SR+CA first-line groups (table 1).

Outcome measure

In table 2, we observed the comparison of outcome measures after being adjusted by model 1 and model 2. There was no significant difference between SR first-line alone group and SR+CA first-line group regarding the successful recanalisation after the first technique alone as the primary outcome (66.8% vs 65.9%, *p*=0.812). In regard to the secondary outcomes, we found that SR+CA first-line group had a larger number of MT device passes (3 (2–4) vs 2 (1–2); model 1, β =1.77, 95% CI=1.55 to 1.99, *p*<0.001; model 2, β =1.76, 95% CI=1.54 to 1.98, *p*<0.001), longer procedure duration (86 (60–129) min vs 80 (50–122) min; β =10.76, 95% CI=1.08 to 20.43, *p*=0.029 (model 1); β =9.96, 95% CI=0.22 to 19.70, *p*=0.045 (model 2)) than SR alone first-line group. Other secondary and safety outcomes were observed to be comparable (all *p*>0.05) between SR alone first-line and SR+CA first-line groups.

Subgroup analysis

Figure 2 showed the results of the subgroup analysis and found significant interaction effects between treatment options and the subgroups stratified by atrial fibrillation (*p* for interaction=0.016) and GA (*p* for interaction=0.036) on the primary outcome.

DISCUSSION

In our study, we found that (1) the number of patients with SR alone first-line was approximately 6.5 times higher than those of patients with SR+CA first-line for acute LVO in the ANGEL-ACT registry; (2) SR+CA first-line led to more MT passes, longer procedure duration and similar successful recanalisation rate after first technique alone compared with first-line SR alone, which varied from the results of the ASTER 2 trial; (3) SR+CA first-line resulted




Figure 1 Flow chart of patient selection. ACA, anterior cerebral artery; CA, contact aspiration; EVT, endovascular thrombectomy; IAT, intra-arterial thrombolysis; mRS, modified Rankin Scale; PCA, posterior cerebral artery; SR, stent retriever.

in similar successful/complete recanalisation rate at the end of the procedure, complete recanalisation after first technique alone, first-pass successful/complete recanalisation rate, NIHSS changed at 24 hours, 90-day mRS 0–2 rate, mortality, PH1 rate, PH2 rate and SICH rate, which was in line with the results of ASTER 2 trial¹²; (4) subgroups stratified by atrial fibrillation and GA had interaction effects with different MT first-line techniques on the primary outcome.

Following the publication of five landmark RCTs in 2015, the American Heart Association/American Stroke Association stroke guideline has suggested SR as the only MT technique for LVO (class I; level of evidence A).¹⁸ As a result, the SR first-line alone has developed and become popular in China since then. Currently, there are still no RCTs demonstrating the superiority of first-line SR+CA over first-line SR alone so far. In real-world practice, first-line SR+CA might increase additional costs compared with first-line SR alone. Meder *et al* reported that switching from SR alone to SR+CA could increase approximately 30% of the direct costs of MT in their institution.⁸ In addition, the AC was not widely used throughout China during the study period, resulting in its non-availability in some hospitals.¹⁶ For the above reasons, the neurointerventionists in China preferred to use the SR alone for the first-line thrombectomy procedure during the study period.

Notably, we found first-line SR+CA had more MT passes, longer procedure duration and a similar successful recanalisation rate after first technique alone

compared with first-line SR alone with the adjustment for the confounders and PS, which was different from the previous studies reported.^{7–12 19 20} Three reasons might explain the difference: first, the high incidence of LVO due to LAA was found high in China, which was reported in 52.7% of patients from the ANGEL-ACT registry,²¹ and patients with LAA were more vascular tortuous. Arterial tortuosity might be associated with LAA,²² which could make it difficult for the AC to reach the thrombus location and thus result in SR+CA first-line group having more MT passes and longer procedure duration than SR alone first-line group. Second, unlike previous studies, the balloon guiding catheter (BGC) was only used in 4% of patients from the ANGEL-ACT registry, which might also lead to different results between our and previous studies. However, Blasco *et al* also found that first-line SR+CA had a longer procedure duration than first-line SR alone, although all patients enrolled in their study used BGC.²³ Third, the experience and preference of the neurointerventionists for the first-line thrombectomy technique might also be another possible explanation. As the procedure of SR+CA combination was more complex than SR alone, less experience for SR+CA combination could result in longer procedure duration, and more MT passes to achieve successful recanalisation.²⁴ During the study period, most neurointerventionists preferred SR alone in order to achieve rapid, successful recanalisation, which might limit the experience of SR+CA combination accumulation and thus lead to the experience relative shortage. Apart from the successful recanalisation

Table 1 Baseline and procedure variables between SR alone first-line and SR+CA first-line groups

Baseline and procedure variables	SR alone first-line (n=1069)	SR+CA first-line (n=164)	P value
Age, years, median (IQR)	65 (55–73)	69 (58–77)	0.007
Male sex, n (%)	684 (64.0)	97 (59.2)	0.231
Transport mode, n (%)			0.846
Mothership	676 (63.2)	105 (64.0)	
Transfer	393 (36.8)	59 (36.0)	
Hypertension, n (%)	606 (56.7)	88 (53.7)	0.466
Diabetes mellitus, n (%)	184 (17.2)	30 (18.3)	0.734
Hyperlipidaemia, n (%)	94 (8.8)	15 (9.2)	0.882
Coronary heart disease, n (%)	166 (15.5)	26 (15.9)	0.915
Atrial fibrillation, n (%)	364 (34.1)	76 (46.3)	0.002
Prior stroke, n (%)	221 (20.7)	44 (26.8)	0.074
Smoking history, n (%)			0.242
Never smoking	666 (62.3)	93 (56.7)	
Previous smoking	72 (6.7)	16 (9.8)	
Current smoking	331 (31.0)	55 (33.5)	
SBP, mm Hg	145 (130–160)	145 (130–158)	0.187
Admission NIHSS*	17 (12–22)	16 (12–21)	0.123
Admission ASPECTS†	9 (7–10)	9 (7–10)	0.490
Blood glucose, mmol/L, median (IQR)	7.1 (6.0–8.8)	6.9 (5.8–7.7)	0.063
Antiplatelets before EVT, n (%)	161 (15.1)	23 (14.0)	0.729
Anticoagulants before EVT, n (%)	50 (4.7)	6 (3.7)	0.560
Pretreatment with IVT, n (%)	280 (26.2)	55 (33.5)	0.049
Occlusion site, n (%)			0.663
ICA	256 (24.0)	38 (23.2)	
M1	496 (46.4)	84 (51.2)	
M2	100 (9.4)	14 (8.5)	
Vertebrobasilar artery	217 (20.3)	28 (17.1)	
Tandem occlusion, n (%)	157 (14.7)	12 (7.3)	0.011
Underlying ICAD, n (%)			0.404
Yes	313 (29.3)	40 (24.4)	
No	644 (60.2)	104 (63.4)	
Undetermined	112 (10.5)	20 (12.2)	
Stroke subtype by TOAST criteria, n (%)			0.062
Large artery atherosclerosis	496 (46.4)	65 (39.6)	
Cardioembolism	394 (36.9)	76 (46.3)	
Other or unknown aetiology	128 (12.0)	13 (7.9)	
Undetermined	51 (4.8)	10 (6.1)	
General anaesthesia, n (%)	440 (41.2)	44 (26.8)	0.001
GP IIb/IIIa receptor inhibitor, n (%)	559 (52.3)	81 (49.4)	0.489

Continued

Table 1 Continued

Baseline and procedure variables	SR alone first-line (n=1069)	SR+CA first-line (n=164)	P value
Heparin during the procedure, n (%)	546 (51.1)	66 (40.2)	0.010
OTP, min, median (IQR)‡	300 (215–440)	295 (225–415)	0.950

Bold values indicate statistical significance
 *Six missing data.
 †Eight missing data.
 ‡Ten missing data.
 ASPECTS, Alberta Stroke Program Early CT Score; CA, contact aspiration; EVT, endovascular thrombectomy; GP, glycoprotein; ICA, intracranial cerebral artery; ICAD, intracranial atherosclerotic disease; IVT, intravenous thrombolysis; M1, middle cerebral artery M1 segment; M2, middle cerebral artery M2 segment; NIHSS, National Institutes of Health Stroke Scale; OTP, onset-to-puncture time; SBP, systolic blood pressure; SR, stent retriever; TOAST, Trial of ORG 10172 in Acute Stroke Treatment criteria.

rate after first technique alone, number of MT passes and procedure duration, our other results aligned with the ASTER 2 trial.¹² Nevertheless, our study showed the high rates of successful recanalisation after all procedures (91.2% vs 85.6% and 91.5% vs 86.2%), complete recanalisation after all procedures (70.2% vs 27.7% and 67.7% vs 32.0%), first-pass complete recanalisation (34.8% vs 17.8% and 34.2% vs 24.1%) and 90-day mRS 0–2 (43.8% vs 41.9% and 43.3% vs 38.0%) compared with the ASTER 2 trial in SR alone first-line and SR+CA first-line, respectively.¹² Therefore, the two first-line thrombectomy techniques seemed to have a similar clinical impact in patients with acute LVO. A recent meta-analysis reported that SR+CA first-line could lead to higher odds of a first-pass effect than SR first-line alone, but similar final recanalisation and functional independence were found between the two groups.²⁵ However, the cost-effectiveness of the entire thrombectomy technique was still known. Future studies are needed to investigate it.

The reasons for recanalisation failure for LVO by MT remains unclear, although previous studies have reported several factors, such as occlusion sites, tandem lesions, underlying ICAD, TOAST subtypes, the added value of IVT, thrombus properties, vascular access problems, embolic complications and failed procedures.^{26–27} We performed the subgroup analysis to explore the potential reasons for recanalisation failure between SR alone first-line and SR+CA first-line. Our study found that SR+CA first-line was less effective than SR alone first-line regarding successful recanalisation after first technique alone for patients with LVO with atrial fibrillation as compared with patients with LVO without atrial fibrillation, possibly due to different thrombus properties (fibrin-rich clots or red blood cell-rich) between patients with atrial fibrillation and those without atrial fibrillation.²⁸ Moreover, our study noted that the SR+CA first-line showed more effective than SR alone first-line when patients with LVO received GA during the procedure. A plausible explanation might be that GA could provide

Table 2 Outcome comparison between SR alone first-line and SR+CA first-line groups

Outcomes	SR alone first-line	SR+CA first-line	Unadjusted model		Adjusted model 1*		Adjusted model 2†	
			Effect size (95% CI)	P value	Effect size (95% CI)	P value	Effect size (95% CI)	P value
Primary outcome								
Successful recanalisation after first technique alone, n(%)‡	714 (66.8)	108 (65.9)	0.96 (0.68 to 1.36)	0.812	0.83 (0.58 to 1.20)	0.323	0.85 (0.60 to 1.22)	0.376
Secondary outcomes								
Complete recanalisation after first technique alone, n(%)§	560 (52.4)	84 (51.2)	0.95 (0.69 to 1.33)	0.781	0.85(0.61-1.20)	0.357	0.86 (0.62 to 1.21)	0.392
First-pass successful recanalisation, n (%)‡††	536 (50.1)	81 (49.4)	0.97 (0.70 to 1.35)	0.858	0.93 (0.67 to 1.30)	0.665	0.95 (0.68 to 1.33)	0.771
First-pass complete recanalisation, n (%)§††	371 (34.8)	56 (34.2)	0.97 (0.69 to 1.38)	0.876	0.93 (0.65 to 1.32)	0.666	0.94 (0.66 to 1.34)	0.731
Number of MT attempts, median (IQR)	2 (1–2)	3 (2–4)	1.81 (1.59 to 2.03)	<0.001	1.77 (1.55 to 1.99)	<0.001	1.76 (1.54 to 1.98)	<0.001
Procedure duration, min, median (IQR)	80 (50–122)	86 (60–129)	5.77 (–3.90 to 15.45)	0.242	10.76 (1.08 to 20.43)	0.029	9.96 (0.22 to 19.70)	0.045
Successful recanalisation after all procedures, n (%)	975 (91.2)	150 (91.5)	1.03 (0.57 to 1.86)	0.915	1.10 (0.61 to 2.00)	0.757	1.12 (0.61 to 2.03)	0.719
Complete recanalisation after all procedures, n (%)	750 (70.2)	111 (67.7)	0.89 (0.63 to 1.27)	0.520	0.86 (0.60 to 1.23)	0.411	0.87 (0.61 to 1.25)	0.461
Rescue treatment								
Switching to other thrombectomy technique after 3 attempts, n (%)	49 (4.6)	11 (6.7)	1.50 (0.76 to 2.94)	0.242	1.27 (0.64 to 2.54)	0.492	1.24 (0.62 to 2.48)	0.538
Balloon angioplasty/stenting, n (%)	160 (15.0)	18 (11.0)	0.70 (0.42 to 1.18)	0.178	0.91 (0.53 to 1.56)	0.731	0.85 (0.50 to 1.45)	0.554
NIHSS score changed at 24 hours, median (IQR)	–5 (–10 to 0)	–4 (–9 to –1)	0.73 (–0.77 to 2.23)	0.338	1.15 (–0.36 to 2.66)	0.135	1.09 (–0.42 to 2.61)	0.157
90-day mRS, median (IQR)	3 (0–5)	3 (0–5)	0.99 (0.91 to 1.08)	0.493	1.12 (0.84 to 1.51)	0.445	1.10 (0.82 to 1.48)	0.527
90-day mRS 0–1, n (%)	423 (39.6)	66 (40.2)	1.03 (0.74 to 1.44)	0.870	1.01 (0.71 to 1.43)	0.957	1.03 (0.73 to 1.44)	0.883
90-day mRS 0–2, n (%)	468 (43.8)	71 (43.3)	0.98 (0.70 to 1.37)	0.907	0.96 (0.68 to 1.36)	0.812	0.97 (0.70 to 1.36)	0.877
90-day mRS 0–3, n (%)	582 (54.4)	92 (56.1)	1.07 (0.77 to 1.49)	0.693	1.06 (0.75 to 1.50)	0.729	1.07 (0.76 to 1.49)	0.714
Safety outcomes								
Intraprocedure embolisation, n (%)	57 (5.3)	13 (7.9)	1.53 (0.82 to 2.86)	0.181	1.24 (0.65 to 2.35)	0.519	1.19 (0.63 to 2.28)	0.591
Parentchymal haemorrhage type 1, n (%)¶	52 (5.0)	9 (5.7)	1.13 (0.55 to 2.35)	0.735	1.09 (0.52 to 2.28)	0.828	1.07 (0.51 to 2.25)	0.857
Parentchymal haemorrhage type 2, n (%)¶	43 (4.2)	7 (4.4)	1.06 (0.47 to 2.41)	0.885	1.04 (0.45 to 2.41)	0.925	0.99 (0.43 to 2.28)	0.987
Symptomatic intracranial haemorrhage, n (%)**	70 (6.8)	14 (8.9)	1.33 (0.73 to 2.42)	0.352	1.32 (0.71 to 2.46)	0.374	1.28 (0.70 to 2.36)	0.427
Any intracranial haemorrhage, n (%)¶	225 (21.7)	42 (26.4)	1.29 (0.88 to 1.89)	0.189	1.25 (0.84 to 1.85)	0.274	1.22 (0.82 to 1.79)	0.326
90-day mRS 6, n (%)	186 (17.4)	20 (12.2)	0.66 (0.40 to 1.08)	0.098	0.68 (0.41 to 1.13)	0.137	0.68 (0.41 to 1.12)	0.127

Bold values indicate statistical significance

*All the baseline variables with p<0.05 in univariable analysis between both groups including age, atrial fibrillation, tandem occlusion, pretreatment with IVT, general anaesthesia and heparin during the procedure were adjusted.

†Adjusted for the propensity score.

‡Defined as mTICI 2b-3.

§Defined as mTICI 3.

¶Thirty-nine missing data.

**Forty-eight missing data.

†† Two missing data.

CA, contact aspiration; IVT, intravenous thrombolysis; mRS, modified Rankin Scale; MT, mechanical thrombectomy; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; SR, stent retriever.




Figure 2 Treatment effects on the primary outcome according to exploratory subgroups. ^aAdjusted for the propensity score. CA, contact aspiration; ICAD, intracranial atherosclerotic disease; IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; SR, stent retriever; TOAST, Trial of ORG 10172 in Acute Stroke Treatment criteria.

greater patient immobilisation and controlled apnoea at critical times during the procedure than no anaesthesia, which allowed the neurointerventionalists to deliver SR and AC to the thrombus location as soon as possible, thereby maximising the effectiveness of SR+CA.²⁹ Accordingly, SR+CA first-line may be more effective than SR alone first-line in certain patients with LVO.

The current comparative analysis had some limitations. First, this study was not a randomised controlled study, which could result in selection bias. Furthermore, some measured or unmeasured variables (eg, neurointerventionalists' experience and preference for first-line thrombectomy technique) could confound our results despite using multiple adjustment models. Second, we did not use the expanded Thrombolysis In Cerebral Infarction score (eTICI)³⁰ instead of mTICI to assess the target vessel recanalisation level since the ANGEL-ACT registry study started much earlier than the study about eTICI was published. Third, SR+CA first-line group had relatively few patients, which may introduce the type II error during the statistical analysis. Fourth, there are several SR+CA

thrombectomy techniques such as 'Solumbra', 'SAVE' (stent retriever-assisted vacuum-locked extraction) and 'ARTS' (aspiration-retriever technique for stroke) which may lead to different recanalisation results.^{31 32} However, we did not collect that variable, which might bias our findings. Finally, as high rate of LAA stroke subtype, long-time duration of workflow before EVT and very low rate of BGC used in the ANGEL-ACT registry^{13 21} might bias the results and could not be generalised to other ethnic populations adequately.

CONCLUSIONS

Our results demonstrated that SR+CA first-line was not superior to SR alone for final recanalisation rate, first-pass recanalisation rate and 90-day clinical outcomes in the Chinese population. The combination of SR and CA first-line was associated with more MT passes and longer procedure duration than SR alone first-line. However, SR+CA first-line may be more effective than SR alone

first-line in certain patients with LVO such as patients undergoing GA or without atrial fibrillation.

Acknowledgements We thank all participating hospitals, relevant clinicians, statisticians, and imaging and laboratory technicians.

Collaborators List of ANGEL-ACT Study group: Beijing Tiantan Hospital, Beijing, China: Zhongrong Miao; Langfang Changzheng Hospital, Hebei, China: Liqiang Gui; Liaocheng Third People's Hospital, Shandong, China: Cunfeng Song; The First People's Hospital of Changzhou, Jiangsu, China: Ya Peng; The Second Affiliated Hospital of Nanjing Medical University, Jiangsu, China: Jin Wu; Fengrun District People's Hospital of Tangshan City, Hebei, China: Shijun Zhao; SiPing Central People's Hospital, Jilin, China: Junfeng Zhao; Yijishan Hospital of Wannan Medical College, Anhui, China: Zhiming Zhou; The Second Affiliated Hospital of Harbin Medical University, Heilongjiang, China: Yongli Li; The Central Hospital of Wuhan, Hubei, China: Ping Jing; The First Hospital of Shijiazhuang, Hebei, China: Lei Yang; Shenzhen Hospital of Southern Medical University, Guangdong, China: Yajie Liu; The People's Hospital of Longhua, Guangdong, China: Qingshi Zhao; Jingjiang People's Hospital, Jiangsu, China: Yan Liu; The Third People's Hospital of Hubei Province, Hubei, China: Xiaoxiang Peng; The Second Affiliated Hospital of Guangzhou Medical University, Guangdong, China: Qingchun Gao; Tianjin TEDA Hospital, Tianjin, China: Zaiyu Guo; Zhangzhou Affiliated Hospital of Fujian Medical University, Fujian, China: Wenhua Chen; Taiyuan Central Hospital, Shanxi, China: Weirong Li; The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China: Xiaojiang Cheng; Affiliated Drum Tower Hospital of Nanjing University Medical School, Jiangsu, China: Yun Xu; The First People's Hospital of Wenling, Zhejiang, China: Yongqiang Zhang; The Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China: Guilian Zhang; The First People's Hospital of Yulin, Guangxi, China: Yijiu Lu; Zhenjiang First People's Hospital, Jiangsu, China: Xinyu Lu; Qitaihe Coal General Hospital Heilongjiang, China: Dengxiang Wang; People's Hospital of Tangshan City, Hebei, China: Yan Wang; Affiliated Hospital of Guilin Medical University, Guangxi, China: Hao Li; The Affiliated Hospital of Guizhou Medical University, Guizhou Province, China: Yang Hua; The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China: Deqin Geng; Qingdao Central Hospital, Shandong, China: Haicheng Yuan; The Fourth People's Hospital of Langfang City, Hebei, China: Hongwei Wang; Beijing Daxing Hospital, Beijing, China: Haihua Yang; Weifang People's Hospital, Shandong, China: Zengwu Wang; Luoyang General Hospital Affiliated to Zhengzhou University, Henan, China: Liping Wei; Dongguan Kanghua Hospital, Guangdong, China: Xuancong Liufu; Shunde Hospital of Southern Medical University, Guangdong, China: Xiangqun Shi; Handan Central Hospital, Hebei, China: Juntao Li; The 981 Hospital of the Chinese People's Liberation Army, Hebei, China: Wenwu Yang; Linfen People's Hospital, Shanxi, China: Wenji Jing; Anshun People's Hospital of Guizhou, China: Xiang Yong; Changle People's Hospital, Shandong, China: Leyuan Wang; The Second People's Hospital of Dongying, Shandong, China: Chunlei Li; Tangshan Gongren Hospital, Hebei, China: Yibin Cao; People's Liberation Army 985th Hospital of the Joint Logistics Support Force, Shanxi, China: Qingfeng Zhu; Gaomi People's Hospital, Shandong, China: Peng Zhang; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China: Xiang Luo; Chongqing Sanxia Center Hospital, Chongqing, China: Shengli Chen; Hospital of Traditional Chinese Medicine of Qiannan, Guizhou, China: Wenwu Peng; Guangdong Hospital of Chinese Medicine, Guangdong, China: Lixin Wang; People's Hospital of Yangjiang, Guangdong, China: Xue Wen; The Third Affiliated Hospital of CQMU, Chongqing, China: Shugui Shi; General Hospital of The Yangtze River Shipping, Hubei, China: Wanming Wang; First People's Hospital of Bijie City, Guizhou, China: Wang Bo; Suqian People's Hospital of Nanjing Drum-Tower Hospital Group, Jiangsu, China: Pu Yuan; Weifang TCM Hospital, Shandong, China: Dong Wang; The Third Affiliated Hospital of Guangzhou Medical University, Guangdong, China: Haitao Guan; Karamay Central Hospital, Xinjiang, China: Wenbao Liang; The Third People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China: Daliang Ma; Wulanchabu City Central Hospital, Inner Mongolia, China: Long Chen; Hospital of Xinjiang Production & Construction Corps, Xinjiang, China: Yan Xiao; Jiaozuo Second People's Hospital, Henan, China: Xiangdong Xie; 904th Hospital of Joint Logistic Support Force of People's Liberation Army, Jiangsu, China: Zhonghua Shi; Ganzhou People's Hospital, Jiangxi, China: Xiangjun Zeng; 967 Hospital of the Joint Logistics Support Force of People's Liberation Army, Liaoning, China: Fanfan Su; The Affiliated Hospital of Northwest University Xi'an No. 3 Hospital, Shaanxi, China: MingZe Chang; The Second Hospital of Liao Cheng, Shandong, China: Jijun Yin; Jilin Province People's Hospital, Jilin, China: Hongxia Sun; People's Hospital of Huanghua City, Hebei, China: Chong Li; Shanghai Fourth People's Hospital, Shanghai, China: Yong Bi; Wanbei Coal-electricity Group General Hospital, Anhui, China: Gang Xie; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China: Yuwu Zhao; Binzhou Medical University Hospital, Shandong, China: Chao Wang;

The 988 Hospital of the People's Liberation Army, Henan, China: Peng Zhang; Linyi People's Hospital, Shandong, China: Xianjun Wang; Yingkou City Central Hospital, Liaoning, China: Dongqun Li; Yantai Shan Hospital, Shandong, China: Hui Liang; Mianyang Central Hospital, Sichuan, China: Zhonglun Chen; Chengdu Fifth People's Hospital, Sichuan, China: Yan Wang; Hengshui Fifth Hospital of Heng Shui City, Hebei, China: Yu Xin Wang; Second Hospital of Dalian Medical University, Liaoning, China: Lin Yin; Boai Hospital of Zhongshan, Guangdong, China: HongKai Qiu; The First People's Hospital of Yibin, Sichuan, China: Jun Wei; Shanxi Provincial People's Hospital, Shanxi, China: Yaxuan Sun; Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Shandong, China: Xiaoya Feng; Chuxiong State People's Hospital, Chuxiong, Yunnan, China: Weihua Wu; The Fourth Affiliated Hospital of China Medical University, Liaoning, China: Lianbo Gao; Taihe Hospital, Shiyan, Hubei, China: Zhibing Ai; Qingdao Municipal Hospital, Shandong, China: Tan Lan; The First People's Hospital of Yunnan Province, Yunnan, China: Li Ding; The No. 2 People's Hospital of Lanzhou, Gansu, China: Qilong Liang; Taizhou First People's Hospital, Zhejiang, China: Zhimin Wang; Hunan Provincial People's Hospital, Hunan, China: Jianwen Yang; First People's Hospital of Changde City, Hunan, China: Ping Xu; Zhejiang Yuyao People's Hospital, Zhejiang, China: Wei Dong; AideBao Hospital, Hebei, China: Quanle Zheng; The First Hospital of Fangshan District, Beijing, China: Zhenyun Zhu; Tianjin Xiqing Hospital, Tianjin, China: Liye Zhao; People's Hospital of Zunhua, Hebei, China: Qingbo Meng; Xingtai Third Hospital, Hebei, China: Yuqing Wei; Qingyuan People's Hospital, Guangdong, China: Xianglin Chen; Fengcheng City Central Hospital, Liaoning, China: Wei Wang; People's Hospital of Hejian City, Hebei, China: Dong Sun; Hangzhou Third People's Hospital, Zhejiang, China: Yongxing Yan; Xiangtan Central Hospital, Hunan, China: Guangxiong Yuan; People's Hospital of Nanpi Country, Hebei, China: Yadong Yang; Liuzhou Railway Central Hospital, Guangxi, China: Jianfeng Zhou; Maoming People's Hospital, Guangdong, China: Zhi Yang; Tongde Hospital of Zhejiang Province, Zhejiang, China: Zhenzhong Zhang; The First Affiliated Hospital of Jinzhou Medical University, Liaoning, China: Ning Guan; Xishan Coal Electricity Group Worker General Hospital, Shaanxi, China: Huihong Wang.

Contributors ZM planned the study. AW analyzed the data. DS and XH interpreted the findings and wrote the manuscript. MH, BJ, XT and GM contributed to data collection. DM, NM and FG provided critical comments/revisions of the manuscript. ZM, DS, R and XH are responsible for the overall content. Guarantor: ZM.

Funding This study was funded by the National Key Research and Development Program of China (grant number 2016YFC1301500).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study involves human participants and was approved by the ethics committees of Beijing Tiantan Hospital, Capital Medical University and each participating site (KY2017-048-01). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Xiaochuan Huo <http://orcid.org/0000-0003-1264-5132>
Dapeng Sun <http://orcid.org/0000-0001-6321-5381>
Baixue Jia <http://orcid.org/0000-0001-8782-5344>
Xu Tong <http://orcid.org/0000-0002-3277-6941>
Gaoting Ma <http://orcid.org/0000-0002-9374-7589>
Ning Ma <http://orcid.org/0000-0002-4909-7048>
Dapeng Mo <http://orcid.org/0000-0001-6641-5573>

REFERENCES

- Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet* 2016;387:1723-31.
- Turc G, Kim AS. First-Line use of contact aspiration or stent retriever thrombectomy for large vessel occlusion stroke. *Stroke* 2019;50:2634-6.

- 3 Lapergue B, Blanc R, Gory B, *et al.* Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: the aster randomized clinical trial. *JAMA* 2017;318:443–52.
- 4 Turk AS, Siddiqui A, Fifi JT, *et al.* Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial. *Lancet* 2019;393:998–1008.
- 5 Eilaghi A, Brooks J, d'Esterre C, *et al.* Reperfusion is a stronger predictor of good clinical outcome than recanalization in ischemic stroke. *Radiology* 2013;269:240–8.
- 6 Di Maria F, Kyheng M, Consoli A, *et al.* Identifying the predictors of first-pass effect and its influence on clinical outcome in the setting of endovascular thrombectomy for acute ischemic stroke: results from a multicentric prospective registry. *Int J Stroke* 2021;16:20–8.
- 7 Okuda T, Arimura K, Matsuo R, *et al.* Efficacy of combined use of a stent retriever and aspiration catheter in mechanical thrombectomy for acute ischemic stroke. *J Neurointerv Surg* 2022;14:892–7.
- 8 Meder G, Żuchowski P, Skura W, *et al.* Mechanical thrombectomy in stroke. experience from switching from stent retriever only to stent retriever combined with aspiration catheter. *J Clin Med* 2021;10:1802.
- 9 Kim SH, Lee H, Kim SB, *et al.* Hybrid mechanical thrombectomy for acute ischemic stroke using an intermediate aspiration catheter and trevo stent simultaneously. *J Clin Neurosci* 2020;76:9–14.
- 10 Colby GP, Baharvahdat H, Mowla A, *et al.* Increased success of single-pass large vessel recanalization using a combined stentriever and aspiration technique: a single institution study. *World Neurosurg* 2019;123:e747–52.
- 11 Hesse AC, Behme D, Kemmling A, *et al.* Comparing different thrombectomy techniques in five large-volume centers: a “real world” observational study. *J Neurointerv Surg* 2018;10:525–9.
- 12 Lapergue B, Blanc R, Costalat V, *et al.* Effect of thrombectomy with combined contact aspiration and stent retriever vs stent retriever alone on revascularization in patients with acute ischemic stroke and large vessel occlusion: the aster2 randomized clinical trial. *JAMA* 2021;326:1158–69.
- 13 Jia B, Ren Z, Mokin M, *et al.* Current status of endovascular treatment for acute large vessel occlusion in china: a real-world nationwide registry. *Stroke* 2021;52:1203–12.
- 14 Lee JS, Hong JM, Lee KS, *et al.* Endovascular therapy of cerebral arterial occlusions: intracranial atherosclerosis versus embolism. *J Stroke Cerebrovasc Dis* 2015;24:2074–80.
- 15 Zaidat OO, Yoo AJ, Khatri P, *et al.* Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. *Stroke* 2013;44:2650–63.
- 16 Tong X, Wang Y, Bauer CT, *et al.* Current status of aspiration thrombectomy for acute stroke patients in china: data from angel-act registry. *Ther Adv Neurol Disord* 2021;14:17562864211007716.
- 17 von Kummer R, Broderick JP, Campbell BCV, *et al.* The heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. *Stroke* 2015;46:2981–6.
- 18 Powers WJ, Derdeyn CP, Biller J, *et al.* 2015 american heart association/american stroke association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the american heart association/american stroke association. *Stroke* 2015;46:3020–35.
- 19 Hafeez MU, Kan P, Srivatsan A, *et al.* Comparison of first-pass efficacy among four mechanical thrombectomy techniques: a single-center experience. *World Neurosurg* 2020;144:e533–40.
- 20 Mohammed MH, Haussen DC, Pisani L, *et al.* Stent-retriever alone vs. aspiration and stent-retriever combination in large vessel occlusion stroke: a matched analysis. *Int J Stroke* 2022;17:465–73.
- 21 Huo X, Sun D, *et al.* Endovascular treatment in acute ischemic stroke with large vessel occlusion according to different stroke subtypes: data from angel-act registry. *Neurol Ther* 2022;11:151–65.
- 22 Kim BJ, Kim SM, Kang DW, *et al.* Vascular tortuosity may be related to intracranial artery atherosclerosis. *Int J Stroke* 2015;10:1081–6.
- 23 Blasco J, Puig J, López-Rueda A, *et al.* Addition of intracranial aspiration to balloon guide catheter does not improve outcomes in large vessel occlusion anterior circulation stent retriever based thrombectomy for acute stroke. *J Neurointerv Surg* 2022;14:863–7.
- 24 Zhu F, Ben Hassen W, Bricout N, *et al.* Effect of operator's experience on proficiency in mechanical thrombectomy: a multicenter study. *Stroke* 2021;52:2736–42.
- 25 Schartz DA, Ellens NR, Kohli GS, *et al.* A meta-analysis of combined aspiration catheter and stent retriever versus stent retriever alone for large-vessel occlusion ischemic stroke. *AJNR Am J Neuroradiol* 2022;43:568–74.
- 26 Kim BM. Causes and solutions of endovascular treatment failure. *J Stroke* 2017;19:131–42.
- 27 Yeo LLL, Bhogal P, Gopinathan A, *et al.* Why does mechanical thrombectomy in large vessel occlusion sometimes fail?: a review of the literature. *Clin Neuroradiol* 2019;29:401–14.
- 28 Jolugbo P, Ariens RAS. Thrombus composition and efficacy of thrombolysis and thrombectomy in acute ischemic stroke. *Stroke* 2021;52:1131–42.
- 29 Campbell D, Diprose WK, Deng C, *et al.* General anesthesia versus conscious sedation in endovascular thrombectomy for stroke: a meta-analysis of 4 randomized controlled trials. *J Neurosurg Anesthesiol* 2021;33:21–7.
- 30 Liebeskind DS, Bracard S, Guillemin F, *et al.* ETICI reperfusion: defining success in endovascular stroke therapy. *J Neurointerv Surg* 2019;11:433–8.
- 31 Yeo LLL, Jing M, Bhogal P, *et al.* Evidence-based updates to thrombectomy: targets, new techniques, and devices. *Front Neurol* 2021;12:712527.
- 32 Munich SA, Vakharia K, Levy EI. Overview of mechanical thrombectomy techniques. *Neurosurgery* 2019;85(suppl_1):S60–7.